ESMO 2023 | Optimizing PSA recurrence treatment

Bertrand Tombal, MD, PhD, Université catholique de Louvain in Ottignies-Louvain-la-Neuve, Belgium, discusses the approved treatments for high-risk PSA recurrence, emphasizing hormone therapy, particularly intermittent androgen deprivation therapy (ADT). Notably, studies show that intermittent ADT performs as well as continuous ADT, with considerations for Gleason score and PSA doubling time. Prof. Tombal introduces the potential of stereotactic radiation therapy for patients with few metastases and discusses the evolving landscape, including the promising combination of ADT and enzalutamide. The Phase III EMBARK (NCT02319837) trial supports the use of this combination, raising questions about the necessity of ADT alone. Prof. Tombal advocates for a personalized approach, optimizing the timing and duration of hormone therapy. This interview took place at the PROSCA/BLADDR 2023 conference in Malaga, Spain.

These works are owned by Magdalen Medical Publishing, protected by global copyright laws, with all rights reserved.